Extensive experience of disease control with gefitinib and the role of prognostic markers

British Journal of Cancer

Volumn 89, Issue , 2003, Pages S3-S8

  Cortes Funes, H ^a   Parra, H Soto ^b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Clinical benefit; Disease control; Egfr; Gefitinib ( Iressa zd1839); Prognostic marker

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; KI 67 ANTIGEN; PROTEIN P27;

ANOREXIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERANCE; FATIGUE; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; NAUSEA; NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; SKIN DISEASE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PALLIATIVE CARE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0346057793     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601476     Document Type: Article

References (19)

1. Arteaga CL (2002) Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7(Suppl 4): 31–39
2. Bailey LR, Kris M, Wolf M, Kay A, Averbuch S, Askaa J, Janas M, Schmidt K, Fukuoka M (2003) Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib (‘Iressa’, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2. Proc Am Assoc Cancer Res 44: 1362 (abs LB-170)
3. Cella D, Natale RB, Lynch TJ, Lee C, Carbone D, Douillard J-Y, Kay A, Wolf M, Heyes A, Ward J (2003) Disease-related symptoms in advanced nonsmall- cell lung cancer as measured by the Lung Cancer Subscale of the FACT-L questionnaire: clinically meaningful improvement with gefitinib (‘Iressa’, ZD1839). Poster presented at ASCO, Chicago, IL, USA, May 31– June 3, Poster no. 2531
4. Douillard J-Y, Giaccone G, Horai T, Noda K, Vansteenkiste JF, Takata I, Gatzeimeir U, Fukuoka K, Macleod A, Feyereislova A, Averbuch S, Nogi Y, Heyes A, Baselga J (2002) Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer (NSCLC) treated with ZD1839 (‘Iressa’) (IDEAL 1). Proc Am Soc Clin Oncol 21: 298a (abs 1195)
5. Fu X-L, Zhu X-Z, Shi D-R, Xiu L-Z, Wang L-J, Zhao S, Qian H, Lu H-F, Xiang Y-B, Jiang G-L (1999) Study of prognostic predictors for non-small cell lung cancer. Lung Cancer 23: 143–152
6. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J-Y, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong R-P, Baselga J (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237– 2246
7. Giaccone G, Johnson D, Scagliotti GV, Manegold C, Rosell R, Rennie P, Wolf M, Averbuch S, Grous J, Fandi A (2003) Results of a multivariate analysis of prognostic factors of overall survival of patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib (ZD1839) in combination with platinum-based chemotherapy (CT) in two large phase III trials (INTACT 1 and 2). Proc Am Soc Clin Oncol 22: 627 (abs 2522)
8. Gips M, Heching Y, Levitt M, Kuten A, Shmueli E, Segal A, Peretz T (2003) The Israeli experience with gefitinib (‘Iressa’, ZD1839) as single agent treatment of advanced non-small-cell lung cancer. Lung Cancer 41(Suppl 2): S247 (abs P-613)
9. Haringhuizen A, Vaessen HFR, Baas P, van Zandwijk N (2003) Gefinitib (‘Iressa’, ZD1839) as a last option for patients with recurrent non-smallcell lung cancer (NSCLC). Poster presented at the 10th WCLC, Vancouver, Canada, August 10–14
10. Herbst R, Giaccone G, Schiller J, Miller V, Natale R, Rennie P, Ochs J, Fandi A, Grous J, Johnson D (2003) Subset analyses of INTACT results for gefitinib (‘Iressa’, ZD1839) when combined with platinum-based chemotherapy for advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 22: 627 (abs 2523)
11. Janas M, Franklin WA, Schmidt K, Bailey LR (2003) Interobserver reproducibility of visually interpreted EGFR immunohistochemical staining in non-small-cell lung cancer. Poster presented at the AACR, Washington, DC, USA, July 11–14, Poster no. LB-213
12. Janne PA, Gurubhagavatula S, Lucca J, Ostler P, Skarin AT, Fidias P, Lynch TJ, Johnson BE (2003) Clinical benefits in patients with advanced nonsmall- cell lung cancer treated with gefitinib (“Iressa”, ZD1839) in the compassionate use program. Lung Cancer 41(Suppl 2): S71 (abs O-243)
13. Kris MG, Natale RB, Herbst RS, Lynch Jr TJ, Prager D, Belini CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC (2003) Efficacy and safety of gefitinib (Iressa, ZD1839), an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with advanced non-small cell lung cancer. A randomized trial. JAMA 22: 2149–2158
14. López Martin A, Constenla M, Martín Algarra S, Salinas P, Massuti B, Gascón P, Castellano D, López-Picazo JM, Rosell R, Cortés-Funes H (2003) Gefitinib (‘Iressa’, ZD1839) in advanced non-small-cell lung cancer patients after progression on chemotherapy. Poster presented at ASCO, Chicago, IL, USA, May 31– June 3, Poster no. 2695
15. Natale RB, Shak S, Aronson N, Averbuch S, Fox W, Luthringer D, Clark K, Baker J, Cronin M, Agus DB (2003) Quantitative gene expression in nonsmall cell lung cancer from paraffin-embedded tissue specimens: predicting response to gefitinib, an EGFR kinase inhibitor. Proc Am Soc Clin Oncol 22: 190 (abs 763)
16. Natale RB, Skarin AT, Maddox AM, Hammond LA, Thomas R, Gandara DR, Gerstein H, Panella TJ, Cole J, Jahanzeb M, Kash J, Hamm J, Langer CJ, Saleh M, Stella PJ, Heyes A, Helms L, Ochs J, Averbuch S, Wolf M, Kay A (2002) Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 (‘Iressa’) in IDEAL 2. Proc Am Soc Clin Oncol 21: 292a (abs 1167)
17. Nicholson RI, Gee JMW, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4): S9–S15
18. Park J, Park B-B, Lee S-H, Park S-H, Lee K-E, Park JO, Kim K, Im Y-H, Kang WK, Park K (2003) Gefitinib (‘Iressa’, ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small-cell lung cancer. Poster presented at the 10th WCLC, Vancouver, Canada, August 10–14
19. Soto Parra H, Cavina R, Zucali PA, Campagnoli E, Latteri F, Morenghi E, Roncalli M, Santoro A (2003) Analysis of responses to gefitinib (‘Iressa’, ZD1839) according to epidermal growth factor receptor expressed as staining intensity or percentage of immunoreactive cells. Poster presented at the 10th WCLC, Vancouver, Canada, August 10–14